Archon Bio develops geometrically tunable protein therapeutics called Antibody Cages (AbCs) by integrating generative AI design with structural control. This platform enables precise engineering of biodistribution, engagement, and function to target previously intractable therapeutic pathways. The company transforms biologics into differentiated drugs by leveraging structural innovation to improve therapeutic effect.
Funding
$20M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
MFounders
Product
Problem
Existing antibody therapies often struggle to effectively target complex disease pathways due to limitations in controlling antibody structure, distribution, and target engagement. This can lead to suboptimal therapeutic outcomes and an inability to address previously intractable drug targets.
Solution
Archon Biosciences is developing Antibody Cages (AbCs), a novel class of protein therapeutics designed using generative AI to overcome the limitations of traditional antibodies. AbCs offer precise control over antibody orientation, valency, size, shape, and rigidity, enabling differentiated distribution and target engagement. This geometric control allows for the creation of molecules with new structures and functions, unlocking challenging therapeutic targets that other technologies cannot reach. The AbC platform facilitates the design of biologics with tunable properties, including agonism, antagonism, and preferential biodistribution, to achieve differentiated therapeutic effects.
Target Audience
The primary target audience includes pharmaceutical companies and research institutions seeking to develop novel biologics with improved targeting and therapeutic efficacy for complex diseases.
Features
- Computationally designed protein therapeutics with geometrically tunable structures
- Precise control over antibody orientation, binding domain valency, size, and shape
- Ability to engineer molecules with differentiated distribution, engagement, and function
- Tunable properties including agonism, antagonism, and preferential biodistribution
- Designed for developability, manufacturability, and optimized drug characteristics
- Scalable generative AI protein design platform for rapid therapeutic iteration